Detalhe da pesquisa
1.
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.
Open Forum Infect Dis
; 9(4): ofac053, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295819
2.
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
Open Forum Infect Dis
; 9(8): ofac406, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36043180